Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017

Learn more about:
Related Clinical Trial
Clinical Precise Diagnosis and Treatment in the Kawasaki Disease A Blood Test to Diagnose Kawasaki Disease Defibrotide in Children With High Risk Kawasaki Disease Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Prevention of Coronary Aneurysms in Kawasaki Syndrome A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Anakinra and Kawasaki Disease Study of Combined Therapy of Aspirin and “IVIG-SN” in Kawasaki Disease Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease Cardiovascular Status of Children 5 Years After Kawasaki Disease Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Etanercept in Kawasaki Disease Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Infliximab (Remicade) for Patients With Acute Kawasaki Disease Acute Abdomen in Kawasaki Disease Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017 Different Doses of IVIG for Kawasaki Disease Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Measurement of Antibodies in Adults With a History of Kawasaki Disease Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Genetic Determinants of Kawasaki Disease Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Brief Title

Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017

Official Title

Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017

Brief Summary

      To investigate the epidemiologic features of Kawasaki disease (KD) in Shanghai from 2013
      through 2017 and identify the risk factors for coronary artery lesions.
    

Detailed Description

      Based on the KD research group network established during the first survey in Shanghai, a set
      of questionnaires and diagnostic guidelines for KD will be sent to 50 hospitals providing
      pediatric medical care in Shanghai, China. Medical records of participants with KD diagnosed
      from January 2013 through December 2017 will be retrospectively analyzed. Data are collected
      by pediatricians, including demographic information, clinical manifestations, prognosis,
      laboratory indexes, treatment and echocardiographic findings.

      Age and seasonal distribution at onset, treatment and cardiac abnormalities wil be described.
      Univariate and multivariate analyses will be performed to identify risk factors for coronary
      artery lesions.
    


Study Type

Observational


Primary Outcome

Incidence of coronary artery lesions

Secondary Outcome

 Incidence of intravenous immunoglobulin resistance

Condition

Mucocutaneous Lymph Node Syndrome

Intervention

no intervention


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

4533

Start Date

June 1, 2017

Completion Date

March 1, 2019

Primary Completion Date

January 1, 2019

Eligibility Criteria

        Inclusion Criteria:

        - meeting the diagnostic criteria for Kawasaki disease released by American Heart
        Association 2017

        Exclusion Criteria:

          -  not in acute phase;

          -  repeated cases;
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Fang Liu, Dr., , 

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT03880929

Organization ID

KD EP4


Responsible Party

Sponsor

Study Sponsor

Children's Hospital of Fudan University

Collaborators

 Shanghai Children's Hospital

Study Sponsor

Fang Liu, Dr., Principal Investigator, Children's Hospital of Fudan University


Verification Date

March 2019